Fibrocell Science Company Profile (NASDAQ:FCSC)

About Fibrocell Science (NASDAQ:FCSC)

Fibrocell Science logoFibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FCSC
  • CUSIP: N/A
  • Web:
  • Market Cap: $41.21 million
  • Outstanding Shares: 14,717,000
Average Prices:
  • 50 Day Moving Avg: $3.04
  • 200 Day Moving Avg: $2.85
  • 52 Week Range: $0.52 - $4.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.64
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $252,000.00
  • Price / Sales: 163.52
  • Book Value: ($0.75) per share
  • Price / Book: -3.73
  • EBITDA: ($18,040,000.00)
  • Return on Equity: -293.07%
  • Return on Assets: -91.03%
  • Current Ratio: 4.78%
  • Quick Ratio: 4.78%
  • Average Volume: 86,857 shs.
  • Beta: 0.39
  • Short Ratio: 3.46

Frequently Asked Questions for Fibrocell Science (NASDAQ:FCSC)

What is Fibrocell Science's stock symbol?

Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC."

How were Fibrocell Science's earnings last quarter?

Fibrocell Science Inc (NASDAQ:FCSC) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.31). View Fibrocell Science's Earnings History.

When will Fibrocell Science make its next earnings announcement?

Fibrocell Science is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Fibrocell Science.

Where is Fibrocell Science's stock going? Where will Fibrocell Science's stock price be in 2017?

3 brokers have issued 1 year target prices for Fibrocell Science's shares. Their forecasts range from $2.00 to $7.60. On average, they expect Fibrocell Science's stock price to reach $5.53 in the next twelve months. View Analyst Ratings for Fibrocell Science.

Who are some of Fibrocell Science's key competitors?

Who are Fibrocell Science's key executives?

Fibrocell Science's management team includes the folowing people:

  • Douglas J. Swirsky, Chairman of the Board
  • John M. Maslowski, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer
  • Lisa A. Embon, Vice President - of Corporate Accounting , Controller
  • Kelvin Moore, Lead Independent Director
  • Julian P. Kirk, Director
  • Marcus E. Smith, Director
  • Marc B. Mazur, Independent Director
  • Christine Thompson St.Clare, Independent Director

How do I buy Fibrocell Science stock?

Shares of Fibrocell Science can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fibrocell Science's stock price today?

One share of Fibrocell Science stock can currently be purchased for approximately $2.80.

MarketBeat Community Rating for Fibrocell Science (NASDAQ FCSC)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Fibrocell Science (NASDAQ:FCSC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.53 (97.62% upside)
Consensus Price Target History for Fibrocell Science (NASDAQ:FCSC)
Price Target History for Fibrocell Science (NASDAQ:FCSC)
Analysts' Ratings History for Fibrocell Science (NASDAQ:FCSC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017HC WainwrightReiterated RatingBuy$7.60N/AView Rating Details
9/11/2017Canaccord GenuityReiterated RatingBuy$3.00 -> $7.00LowView Rating Details
3/7/2017Rodman & RenshawInitiated CoverageBuy -> Buy$2.00N/AView Rating Details
7/6/2016Griffin SecuritiesReiterated RatingBuy$12.00N/AView Rating Details
6/8/2016Roth CapitalReiterated RatingBuy$5.00N/AView Rating Details
6/8/2016WedbushReiterated RatingNeutral$1.50 -> $4.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Fibrocell Science (NASDAQ:FCSC)
Earnings by Quarter for Fibrocell Science (NASDAQ:FCSC)
Earnings History by Quarter for Fibrocell Science (NASDAQ FCSC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.31)($0.31)ViewListenView Earnings Details
5/10/2017Q1 2017($0.29)($0.58)ViewN/AView Earnings Details
11/3/2016Q316($0.15)($0.05)$0.07 million$0.22 millionViewN/AView Earnings Details
3/10/2016Q415($0.17)($0.40)$0.07 million$0.08 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.07)$0.06 million$0.08 millionViewN/AView Earnings Details
8/6/2015Q215($0.16)($0.17)$0.09 million$0.14 millionViewN/AView Earnings Details
5/8/2015Q1 2015($0.16)($0.17)$0.05 million$0.19 millionViewN/AView Earnings Details
3/13/2015Q4 2014($0.16)($0.16)$0.06 million$0.06 millionViewN/AView Earnings Details
11/7/2014Q3 14($0.14)($0.17)$0.06 million$0.02 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.18)($0.08)$0.07 million$0.06 millionViewN/AView Earnings Details
5/19/2014Q114($0.15)($0.35)$0.05 million$0.05 millionViewN/AView Earnings Details
3/17/2014Q414($0.26)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Fibrocell Science (NASDAQ:FCSC)
2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.31)($0.07)($0.19)
Q2 20174($0.34)($0.07)($0.20)
Q3 20174($0.35)($0.05)($0.20)
Q4 20173($0.37)($0.05)($0.20)
Q1 20181($0.26)($0.26)($0.26)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)


Dividend History for Fibrocell Science (NASDAQ:FCSC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Fibrocell Science (NASDAQ:FCSC)
Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 54.70%
Insider Trades by Quarter for Fibrocell Science (NASDAQ:FCSC)
Institutional Ownership by Quarter for Fibrocell Science (NASDAQ:FCSC)
Insider Trades by Quarter for Fibrocell Science (NASDAQ:FCSC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016David PernockChairmanBuy50,000$0.92$46,000.00View SEC Filing  
11/13/2015David PernockCEOBuy3,000$5.00$15,000.00View SEC Filing  
8/11/2015David PernockCEOBuy3,500$6.54$22,890.00View SEC Filing  
7/27/2015Randal J KirkMajor ShareholderBuy975,987$5.80$5,660,724.60View SEC Filing  
5/13/2015David PernockCEOBuy16,600$4.30$71,380.00View SEC Filing  
12/12/2014David PernockCEOBuy5,000$2.52$12,600.00View SEC Filing  
11/20/2014David PernockCEOBuy5,000$2.54$12,700.00View SEC Filing  
11/20/2014John Michael MaslowskiVPBuy1,000$2.54$2,540.00View SEC Filing  
6/5/2014Christine St.ClareDirectorBuy10,000$3.00$30,000.00View SEC Filing  
6/5/2014David PernockCEOBuy12,500$2.95$36,875.00View SEC Filing  
6/4/2014Kelvin MooreDirectorBuy4,557$2.99$13,625.43View SEC Filing  
6/4/2014Randal J KirkMajor ShareholderBuy400,000$2.90$1,160,000.00View SEC Filing  
1/24/2014Randal J KirkMajor ShareholderBuy1,024,590$4.88$4,999,999.20View SEC Filing  
11/21/2013David PernockCEOBuy10,000$3.69$36,900.00View SEC Filing  
11/20/2013Gregory L WeaverCFOBuy10,000$3.51$35,100.00View SEC Filing  
10/1/2013Randal J KirkMajor ShareholderBuy3,658,536$4.10$14,999,997.60View SEC Filing  
7/26/2013Randal J KirkMajor ShareholderBuy1,243,781$6.03$7,499,999.43View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Fibrocell Science (NASDAQ:FCSC)
Latest Headlines for Fibrocell Science (NASDAQ:FCSC)
DateHeadline logoReviewing NovaBay Pharmaceuticals (NBY) & Fibrocell Science (FCSC) - October 20 at 6:46 AM logoFibrocell Science: A Very Appealing Gene Therapy Play - Seeking Alpha - October 19 at 7:21 PM logoFibrocell Science Inc (FCSC) Upgraded to Hold at Zacks Investment Research - October 10 at 7:40 PM logoFibrocell Science Inc (FCSC) Receives Buy Rating from HC Wainwright - October 5 at 10:08 AM logo Brokerages Anticipate Fibrocell Science Inc (FCSC) to Announce -$0.41 Earnings Per Share - October 4 at 6:26 PM logoFibrocell to Present at 2017 Cell & Gene Meeting on the Mesa - October 2 at 7:39 PM logoHC Wainwright Raises Fibrocell Science Inc (FCSC) Price Target to $7.60 - September 26 at 11:18 AM logoFibrocell Science (FCSC) vs. Its Competitors Head to Head Contrast - September 25 at 12:26 AM logoImplied Volatility Surging for Fibrocell Science (FCSC) Stock Options - Nasdaq - September 24 at 4:15 AM logoImplied Volatility Surging for Fibrocell Science (FCSC) Stock Options - September 23 at 9:44 AM logoFibrocell Science Inc (FCSC) Stock Rating Reaffirmed by Canaccord Genuity - September 17 at 10:22 PM logo Analysts Expect Fibrocell Science Inc (FCSC) to Post -$0.41 Earnings Per Share - September 16 at 12:08 AM logoFibrocell Science Inc (FCSC) Coverage Initiated by Analysts at HC Wainwright - September 15 at 7:28 AM logoFibrocell Science (FCSC) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 11 at 7:09 PM logo10 Biggest Mid-Day Gainers For Friday - Benzinga - September 8 at 7:03 PM logoFibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes’ 2017 RARE Patient Advocacy Summit - September 5 at 8:14 PM logoBrokers Offer Predictions for Fibrocell Science Inc's Q1 2018 Earnings (FCSC) - August 14 at 6:58 AM logoFibrocell Science Inc (NASDAQ:FCSC) Posts Quarterly Earnings Results, Meets Expectations - August 11 at 2:06 PM logo Analysts Anticipate Fibrocell Science Inc (NASDAQ:FCSC) to Post -$0.31 EPS - August 10 at 8:06 AM logoFibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights - August 9 at 6:47 PM logoFibrocell Science reports 2Q loss - August 9 at 6:46 PM logoFibrocell to Present at Canaccord Genuity 37th Annual Growth Conference - August 3 at 3:40 PM logoFibrocell Science Inc (NASDAQ:FCSC) Set to Announce Earnings on Wednesday - August 3 at 10:58 AM logoWhat's in Store for Intrexon (XON) in this Earnings Season? - August 2 at 7:29 PM logoFibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights - August 2 at 7:29 PM logoWhat's in Store for Intrexon (XON) in this Earnings Season? - August 2 at 7:29 PM logo-$0.31 EPS Expected for Fibrocell Science Inc (NASDAQ:FCSC) This Quarter - July 20 at 10:15 PM logoXLRN's DART Misses Mark, RGLS Makes Cuts In Pipeline, FDA Snubs CHRS - June 13 at 11:33 AM logoFibrocell Science (FCSC) Announces Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma - June 13 at 11:33 AM logoWhy 2 rare pediatric disease designations could bring big bucks for Exton gene therapy developer - June 12 at 6:01 PM logoFibrocell Science (FCSC) Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for RDEB - June 8 at 6:11 PM logoFibrocell Science's (FCSC) CEO John Maslowski on Q1 2017 Results - Earnings Call Transcript - May 12 at 10:44 PM logoIntrexon (XON) Q1 Loss Wider than Expected, Revenues Beat - May 11 at 5:46 PM logoFibrocell Science reports 1Q loss - May 10 at 8:33 AM logoFibrocell Science (FCSC) Announces DSMB Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of RDEB - May 8 at 9:03 AM logoFibrocell Science Inc. (FCSC) Has Climbed To A 1-Month High - April 13 at 11:14 AM logoFibrocell Science (FCSC) Announces Compliance with NASDAQ Listing Requirements - March 28 at 11:50 AM logoFibrocell Science (FCSC) Plans 1-for-3 Reverse Stock Split - March 10 at 11:18 AM logoFibrocell Announces One-for-Three Reverse Stock Split - March 10 at 11:18 AM logoFIBROCELL SCIENCE, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Articl - March 10 at 11:18 AM logoQ4 2016 Fibrocell Science Inc Earnings Release - Before Market Open - March 9 at 5:38 PM logoFIBROCELL SCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E - March 9 at 5:38 PM logoFIBROCELL SCIENCE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Fin - March 8 at 5:58 PM logoBenzinga's Top Upgrades, Downgrades For March 7, 2017 - Benzinga - March 8 at 8:05 AM logo4:55 pm Fibrocell Science entered into securities purchase agreement with existing investors for sale of $8.0 mln Series A Convertible Preferred Stock and accompanying warrants - March 7 at 11:11 PM logoFIBROCELL SCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib - March 3 at 11:50 PM logoFIBROCELL SCIENCE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - March 1 at 9:54 PM logoFibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa - February 23 at 5:11 PM logoFIBROCELL SCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers - February 13 at 9:38 AM logoFIBROCELL SCIENCE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - January 9 at 5:59 PM



Fibrocell Science (FCSC) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.